Latest News in the pharma Industry

Research & Development

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

13 Nov 2014

Read more 
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab

Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab

13 Nov 2014

Read more 
First Wave of Phase III Development Programme for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit NDA in 2015

First Wave of Phase III Development Programme for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit NDA in 2015

13 Nov 2014

Read more 
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase III Study Of Brodalumab

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase III Study Of Brodalumab

12 Nov 2014

Read more 
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma

11 Nov 2014

Read more 
New Drug for Common Liver Disease Improves Liver Health

New Drug for Common Liver Disease Improves Liver Health

10 Nov 2014

Read more 
Almac Launches CLIA Validated Next Generation Sequencing Assay for P53 Mutations

Almac Launches CLIA Validated Next Generation Sequencing Assay for P53 Mutations

10 Nov 2014

Read more 
Interim Data from Study of Merck's Investigational Hepatitis C Treatment to be Presented at The Liver Meeting

Interim Data from Study of Merck's Investigational Hepatitis C Treatment to be Presented at The Liver Meeting

10 Nov 2014

Read more 
LINDIS Biotech Consolidates Onco-Immune, Trifunctional, Bispecific Antibody IP and Know-How from TRION Pharma

LINDIS Biotech Consolidates Onco-Immune, Trifunctional, Bispecific Antibody IP and Know-How from TRION Pharma

10 Nov 2014

Read more 
VR315 US Development Milestone

VR315 US Development Milestone

7 Nov 2014

Read more 
Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence

Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence

7 Nov 2014

Read more 
Amgen Announces Top-Line Secondary Endpoint Results of Phase III Trebananib TRINOVA-1 Trial In Patients with Recurrent Ovarian Cancer

Amgen Announces Top-Line Secondary Endpoint Results of Phase III Trebananib TRINOVA-1 Trial In Patients with Recurrent Ovarian Cancer

5 Nov 2014

Read more